ArticleNaunyn-Schmiedeberg's archives of pharmacology2008
Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Targeted HA@Que-Mn nanozymes alleviate postherpetic neuralgia by modulating neuroinflammation.Materials today. Bio · 2026Article
- APurinergic signalling · 2025Review
- Adenosine Receptors as Potential Therapeutic Analgesic Targets.International journal of molecular sciences · 2023Review
- Adenosine signaling mediate pain transmission in the central nervous system.Purinergic signalling · 2023Review
- The role of adenosine receptor ligands on inflammatory pain: possible modulation of TRPV1 receptor function.Inflammopharmacology · 2023Article
- Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.International journal of molecular sciences · 2020Review
- Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels.The Journal of cell biology · 2020Article
- Inhibition of Adenosine Pathway Alters Atrial Electrophysiology and Prevents Atrial Fibrillation.Frontiers in physiology · 2020Article
- Article
- Adenosine AJournal of clinical medicine · 2017Review
- The Role of Adenosine Signaling in Headache: A Review.Brain sciences · 2017Review
- Fluorinated Adenosine AInternational journal of medicinal chemistry · 2017Article
- Evidence for A1 and A 3 receptors mediating adenosine-induced intracellular calcium release in the dorsal root ganglion neurons by using confocal microscopy imaging.Lasers in medical science · 2014Article
- Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies.Bioorganic & medicinal chemistry · 2013Article
- Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Pharmacology & therapeutics · 2011Review
- Recent developments in adenosine receptor ligands and their potential as novel drugs.Biochimica et biophysica acta · 2011Review
- Xanthines as adenosine receptor antagonists.Handbook of experimental pharmacology · 2011Review
- Adenosine A(2) receptors modulate tubuloglomerular feedback.American journal of physiology. Renal physiology · 2010Article
- Adenosine A(2A) agonist and A(2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation.Purinergic signalling · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we examined the effects of systemic and local administration of the subtype-selective adenosine receptor antagonists PSB-36, PSB-1115, MSX-3, and PSB-10 on inflammation and inflammatory hyperalgesia. Pharmacological blockade of adenosine receptor subtypes after systemic application of antagonists generally led to a decreased edema formation after formalin injection and, with the exception of A(3) receptor antagonism, also after the carrageenan injection. The selective A(2B) receptor antagonist PSB-1115 showed a biphasic, dose-dependent effect in the carrageenan test, increasing edema formation at lower doses and reducing it at a high dose. A(1) and A(2B) antagonists diminished pain-related behaviors in the first phase of the formalin test, while the second, inflammatory phase was attenuated by A(2B) and A(3) antagonists. The A(2B) antagonist was particularly potent in reducing inflammatory pain dose-dependently reaching the maximum effect at a low dose of 3 mg/kg. Inflammatory hyperalgesia was totally eliminated by the A(2A) antagonist MSX-3 at a dose of 10 mg/kg. In contrast to the A(1) antagonist, the selective antagonists of A(2A), A(2B), and A(3) receptors were also active upon local administration. Our results demonstrate that the blockade of adenosine receptor subtypes can decrease the magnitude of inflammatory responses. Selective A(2A) antagonists may be useful for the treatment of inflammatory hyperalgesia, while A(2B) antagonists have potential as analgesic drugs for the treatment of inflammatory pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.